Stock News and Filings Feed


Add AUP
to your dashboard

3 Reasons to Buy Aurinia Pharmaceuticals Stock Right Now

2017-08-17 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. (0-4)

Aurinia: Strong Potential With Focus On Lupus Related Kidney Ailment

2017-08-16 seekingalpha
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) stock showed impressive growth of over 188 percent in this year so far. However, it is currently considerably lower than its peak price of $10.54. The company also recently presented several positive news regarding its lead drug candidate voclosporin, including the dosing of the first patient in Phase III trial. At the current depressed price point, Aurinia is a good choice for investors with medium to long term investment horizon. (0-1)

Pulse Biosciences: It's All Relative - The Qualitative Aspect Of Insider Behavior

2017-08-09 seekingalpha
Private investor Robert Duggan's recent buys extend the window to February before he can sell shares. (0-4)

An Exciting New Drug Is in Clinical Trials for Aurinia Pharmaceuticals

2017-07-25 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

3 Been-There-Done-That Biotech CEOs Who Are Doing it Again

2017-07-21 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

3 Hottest Biotech Stocks of 2017 -- Are They Still Buys Now?

2017-07-21 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

3 Small Biotech Stocks Being Run by Proven Winners

2017-07-17 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

Is Aurinia Pharmaceuticals' Management Its Best Asset?

2017-07-15 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

After Its Drop, Is Aurinia Pharmaceuticals Stock Now A Buy?

2017-07-13 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

Institutional Ownership Swells At Well-Funded Aurinia Pharmaceuticals

2017-07-11 seekingalpha
Clinical trials undertaken so far have demonstrated that voclosporin is a safe and effective treatment for lupus nephritis. There are indications that voclosporin may have significant potential in treating diseases.

Options Traders Expect Huge Moves in Aurinia Pharmaceuticals (AUPH) Stock

2017-07-10 zacks
Investors in Aurinia Pharmaceuticals Inc (AUPH - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 21st 2017 $2.50 Put had some of the highest implied volatility of all equity options today.

Aurinia Pharmaceuticals: Phase III Design Gleaned From Phase II Study

2017-07-06 seekingalpha
Aurinia Pharmaceuticals (AUPH)’s Phase III (AURORA) design is nearly identical to the promising Phase II (AURA) study.

venBio Global Strategic Fund, L.P. Announces Update to Stake in Aurinia Pharmaceuticals Inc.

2017-07-05 marketwired
SAN FRANCISCO, CALIFORNIA--(Marketwired - July 5, 2017) - venBio Global Strategic Fund, L.P. ("venBio") announced today that as a result of the closing on March 14, 2017 of a public offering (the "Offering") of 22,300,000 common shares ("Common Shares") by Aurinia Pharmaceuticals Inc. (the "Company"), the number of Common Shares held by venBio decreased to less than 10% of the issued and outstanding Common Shares.

Athersys And Aurinia Target Human And Animal Health

2017-06-26 seekingalpha
Athersys and Aurinia Pharmaceuticals are both engaged in late stage clinical trials of treatments for human diseases.

Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't?

2017-06-20 zacks
Investors in Aurinia Pharmaceuticals Inc.(AUPH - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the July 21st, 2017 $2.50 Put had some of the highest implied volatility of all equity options today.

New Data Suggests Aurinia Pharmaceuticals Is Onto Something Big

2017-06-17 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

Aurinia Pharma Rises Following Updated Mid-Stage Results

2017-06-16 247wallst
Shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) saw a handy gain on Friday after the firm presented new data from its mid-stage study in lupus nephritis (LN) during the Annual European Congress of Rheumatology (EULAR) 2017. The updated data came from the firm’s global Phase 2b AURA-LV study.

Technical Snapshots for These Biotech Stocks -- Gilead Sciences, Aurinia Pharma, Esperion Therapeutics, and Alexion Pharma

2017-06-08 prnewswire
DailyStockTracker.com has issued research reports on Gilead Sciences Inc. (NASDAQ: GILD), Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), Esperion Therapeutics Inc. (NASDAQ: ESPR), and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). According to Oppenheimer's Leah Rush Cann, Biotech stocks are trading at a 30% premium to the market. The group had a price-to-earnings-growth ratio of 1.86 times versus the S&P 500's PEG ratio 1.

Revisiting Conatus Pharmaceuticals Due To Recent Pipeline Expansion Talks

2017-05-15 seekingalpha
Since initiating a partnership deal with Novartis back in December of 2016, Conatus has been on a tear, hitting highs of $9+/share.

Is a Surprise Coming for Aurinia Pharmaceuticals (AUPH) This Earnings Season?

2017-05-09 zacks
Investors are always looking for stocks that are poised to beat at earnings season and Aurinia Pharmaceuticals Inc. (AUPH - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store?

2017-05-09 zacks
Perrigo Company plc (PRGO - Free Report) is expected to report first-quarter 2017 results later this month. The company did not report earnings results for the fourth quarter of 2016. However, in the other three quarters the company had a mixed track record as it beat expectations in two of the last three quarters and missed the same in one. Overall, the company has an average positive earnings surprise of 0.

What's in the Cards for Repros (RPRX) this Earnings Season?

2017-05-05 zacks
Repros Therapeutics Inc. (RPRX - Free Report) is expected to report first-quarter 2017 results this month. Let’s see how things are shaping up for this quarter.

Will Intrexon (XON) Pull Off a Surprise in Q1 Earnings?

2017-05-03 zacks
Intrexon Corporation (XON - Free Report) is expected to report first-quarter 2017 results on May 9.

3 Best Biotech Stocks During Trump's First 100 Days

2017-05-01 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

Aurinia Pharmaceuticals Is A Top Pick For H2 2017

2017-05-01 seekingalpha
Patients with current therapy have been looking for a drug to reduce the toxicity of steroids.